The Fragile X-Associated Disorders And Targeted Treatments Dr. Hagerman does have a financial interest/arrangement or affiliation with Neuropharm & Seaside Therapeutics, Roche and is a consultant for Novaritis for mGluR5 studies that could be perceived as a real or apparent conflict of interest in the context of the subject of her presentation. She will be discussing the use of targeted treatments in Fragile X Syndrome include mGluR5 antagonists and minocycline and GABA agonists. (Javascript is required to view Mediasite content)